|
US2631173A
(en)
|
1949-01-04 |
1953-03-10 |
Phillips Petroleum Co |
Production of cyclooctadiene
|
|
IL54795A
(en)
|
1978-05-26 |
1980-10-26 |
Yeda Res & Dev |
Analgesic compositions comprising substituted bicyclic and spiroaliphatic amines and certain novel compounds of these types
|
|
DE68916959T2
(de)
|
1988-03-02 |
1995-01-19 |
Uab Research Foundation |
Reversibel mechanisch-chemisch arbeitende maschinen, die aus bioelastomeren bestehen, die zu regelbaren inversen temperaturübergängen fähig sind, zur umwandlung von chemischer in mechanische arbeit.
|
|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
US6100099A
(en)
|
1994-09-06 |
2000-08-08 |
Abbott Laboratories |
Test strip having a diagonal array of capture spots
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
US6136603A
(en)
|
1999-03-26 |
2000-10-24 |
Isis Pharmaceuticals Inc. |
Antisense modulation of interleukin-5 signal transduction
|
|
AU3412801A
(en)
|
2000-02-22 |
2001-09-03 |
Banyu Pharma Co Ltd |
Novel imidazoline compounds
|
|
JP2003533986A
(ja)
|
2000-05-04 |
2003-11-18 |
エイブイアイ バイオファーマ， インコーポレイテッド |
スプライス領域アンチセンス組成物および方法
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
WO2003078960A2
(en)
|
2002-03-11 |
2003-09-25 |
Momenta Pharmaceuticals, Inc. |
Analysis of sulfated polysaccharides
|
|
DK2284266T3
(da)
|
2002-11-14 |
2014-01-13 |
Thermo Fisher Scient Biosciences Inc |
sIRNA-MOLEKYLE MOD TP53
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
DK2752488T3
(da)
|
2002-11-18 |
2020-04-20 |
Roche Innovation Ct Copenhagen As |
Antisense-design
|
|
EP2135948B1
(en)
|
2002-11-25 |
2014-09-17 |
Masafumi Matsuo |
ENA nucleic acid drugs modifying splicing in mRNA precursor
|
|
ES2361924T3
(es)
|
2002-12-20 |
2011-06-24 |
X-Ceptor Therapeutics, Inc. |
Derivados de isoquinolinona y su uso como agentes terapéuticos.
|
|
WO2004069991A2
(en)
|
2003-02-10 |
2004-08-19 |
Santaris Pharma A/S |
Oligomeric compounds for the modulation of survivin expression
|
|
CA2524255C
(en)
|
2003-03-21 |
2014-02-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
EP1620564A4
(en)
|
2003-04-18 |
2008-03-12 |
Cytovia Inc |
METHODS FOR TREATING DISEASES INDUCING APOPTOSIS INDUCTION AND SCREENING ASSAYS
|
|
US7442372B2
(en)
|
2003-08-29 |
2008-10-28 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
|
ES2344302T3
(es)
|
2004-02-10 |
2010-08-24 |
Zystor Therapeutics , Inc. |
Alfa glucosidasa acida y fragmentos de la misma.
|
|
US8404747B2
(en)
|
2004-03-05 |
2013-03-26 |
The General Hospital Corporation |
Compositions and methods for modulating interaction between polypeptides
|
|
WO2005113571A2
(en)
|
2004-05-13 |
2005-12-01 |
The University Of North Carolina At Chapel Hill |
Methods for the delivery of oligomeric compounds
|
|
JP5697297B2
(ja)
|
2004-05-14 |
2015-04-08 |
ロゼッタ ジノミクス リミテッド |
マイクロｎａｓおよびその使用
|
|
ATE498685T1
(de)
|
2004-06-28 |
2011-03-15 |
Univ Western Australia |
Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
|
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
WO2006022688A1
(en)
|
2004-08-06 |
2006-03-02 |
Applera Corporation |
Diagnosis of pancreatic cancer by using pancreatic targets
|
|
FR2874384B1
(fr)
|
2004-08-17 |
2010-07-30 |
Genethon |
Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
|
|
PT1812031E
(pt)
|
2004-11-01 |
2015-10-01 |
Univ California |
Composições e métodos para modificação de biomoléculas
|
|
US8431558B2
(en)
|
2004-11-01 |
2013-04-30 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
US20120122801A1
(en)
|
2005-01-05 |
2012-05-17 |
Prosensa B.V. |
Mannose-6-phosphate receptor mediated gene transfer into muscle cells
|
|
WO2006091796A2
(en)
|
2005-02-22 |
2006-08-31 |
Acucela, Inc. |
Compositions and methods for diagnosing and treating retinal diseases
|
|
JP2009511023A
(ja)
|
2005-10-06 |
2009-03-19 |
ユニバーシティー、オブ、デラウェア |
ハンチントン病の治療のためのｇに富むポリヌクレオチド
|
|
JP2007104971A
(ja)
|
2005-10-14 |
2007-04-26 |
New Industry Research Organization |
ミオスタチンのスプライシング制御アンチセンスオリゴヌクレオチド
|
|
US20090214531A1
(en)
|
2006-01-30 |
2009-08-27 |
John Mekalanos |
Methods and Compositions for Treating and Preventing Bacterial Infections
|
|
CA2641359C
(en)
|
2006-02-09 |
2022-10-04 |
Genzyme Corporation |
Slow intraventricular delivery
|
|
US20070249014A1
(en)
|
2006-02-10 |
2007-10-25 |
Invitrogen Corporation |
Labeling and detection of post translationally modified proteins
|
|
US8859752B2
(en)
|
2006-04-18 |
2014-10-14 |
The Trustees Of The University Of Pennsylvania |
SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
|
|
WO2007136989A2
(en)
|
2006-05-05 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of dgat2
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
WO2008018795A1
(en)
|
2006-08-11 |
2008-02-14 |
Prosensa Technologies B.V. |
Methods and means for treating dna repeat instability associated genetic disorders
|
|
JP5665317B2
(ja)
|
2006-10-18 |
2015-02-04 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
アンチセンス化合物
|
|
ES2569365T3
(es)
|
2006-11-29 |
2016-05-10 |
Nationwide Children's Hospital |
Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular
|
|
PT2457919T
(pt)
|
2007-01-18 |
2019-09-20 |
Genzyme Corp |
Oligossacáridos compreendendo um grupo amino-oxi e os seus conjugados
|
|
DK2149605T3
(da)
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
|
EP2149605B1
(en)
|
2007-03-22 |
2013-07-03 |
Santaris Pharma A/S |
Short RNA antagonist compounds for the modulation of target mRNA
|
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
|
PT2203173E
(pt)
|
2007-10-26 |
2016-03-15 |
Academisch Ziekenhuis Leiden |
Resumo
|
|
WO2009075815A1
(en)
|
2007-12-07 |
2009-06-18 |
Duke University |
Immunomodulating gene therapy
|
|
WO2009124295A2
(en)
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US20110130346A1
(en)
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
HUE025212T2
(en)
|
2008-07-08 |
2016-03-29 |
Univ Duke |
A method for treating glycogen storage disease
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
TR201902952T4
(tr)
|
2008-10-24 |
2019-03-21 |
Sarepta Therapeutics Inc |
Dmd için ekson atlama bileşimleri.
|
|
DK2344637T4
(en)
|
2008-10-27 |
2018-04-23 |
Biomarin Tech Bv |
Methods and means for efficiently skipping exon 45 in Duchenne muscular dystrophy pre-mRNA
|
|
BR122020010601B8
(pt)
|
2008-12-16 |
2021-07-27 |
Genzyme Corp |
conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas
|
|
US8466340B2
(en)
|
2009-02-18 |
2013-06-18 |
Amicus Therapeutics, Inc. |
Mouse model for pompe disease and methods of use thereof
|
|
NZ595955A
(en)
|
2009-04-24 |
2012-10-26 |
Prosensa Technologies Bv |
Oligonucleotide comprising an inosine for treating dmd
|
|
CN102459597B
(zh)
*
|
2009-05-08 |
2020-06-30 |
库尔纳公司 |
通过针对dmd家族的天然反义转录物的抑制治疗肌营养蛋白家族相关疾病
|
|
EP3679942A1
(en)
|
2009-06-17 |
2020-07-15 |
BioMarin Pharmaceutical Inc. |
Formulations for lysosomal enzymes
|
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
|
WO2011036640A2
(en)
|
2009-09-24 |
2011-03-31 |
Cellectis |
Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
|
|
CA2780563C
(en)
|
2009-11-12 |
2025-05-06 |
Univ Western Australia |
Antisense Molecules and Methods for Treating Pathologies
|
|
WO2011078797A2
(en)
|
2009-12-22 |
2011-06-30 |
Singapore Health Services Pte. Ltd |
Antisense oligonucleotides and uses threreof
|
|
WO2011130164A2
(en)
|
2010-04-13 |
2011-10-20 |
The Regents Of The University Of California |
Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
|
|
US20110256157A1
(en)
|
2010-04-15 |
2011-10-20 |
Spirogen Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
ES2527536T7
(es)
|
2010-04-27 |
2016-03-08 |
Synaffix B.V. |
Compuestos de ciclooctina fusionada y su uso en reacciones clic sin metales
|
|
EP2576574A2
(en)
|
2010-05-28 |
2013-04-10 |
Sarepta Therapeutics, Inc. |
Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
EP2593142B8
(en)
|
2010-07-12 |
2018-12-26 |
Pfizer Healthcare Ireland |
Multifunctional antibody conjugates
|
|
KR20180105730A
(ko)
|
2010-07-19 |
2018-09-28 |
아이오니스 파마수티컬즈, 인코포레이티드 |
근육긴장성 이영양증-단백질 키나제(dmpk) 발현의 조절 방법
|
|
US10865445B2
(en)
|
2010-08-18 |
2020-12-15 |
Fred Hutchinson Cancer Research Center |
Methods for alleviating facioscapulohumeral dystrophy (FSHD) by N siRNA molecule inhibiting the expression of DUX4-FL
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
US20120225034A1
(en)
|
2010-09-02 |
2012-09-06 |
Universite De Mons |
Agents useful in treating facioscapulohumeral muscular dystrophy
|
|
EA034333B1
(ru)
|
2010-11-30 |
2020-01-29 |
Дженентек, Инк. |
Варианты антитела для переноса соединения через гематоэнцефалический барьер
|
|
WO2012109296A1
(en)
|
2011-02-08 |
2012-08-16 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center |
Antisense oligonucleotides
|
|
EP2673361B1
(en)
|
2011-02-08 |
2016-04-13 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
WO2012144906A1
(en)
|
2011-04-22 |
2012-10-26 |
Prosensa Technologies B.V. |
New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1)
|
|
CN103732259A
(zh)
|
2011-06-24 |
2014-04-16 |
森彻斯有限公司 |
细胞外靶向药物缀合物
|
|
ES2990023T3
(es)
*
|
2011-07-25 |
2024-11-28 |
Nationwide Childrens Hospital Inc |
Productos de virus recombinantes y métodos para inhibición de la expresión de DUX4
|
|
WO2013019623A2
(en)
|
2011-07-29 |
2013-02-07 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject
|
|
EP2753607B1
(en)
|
2011-09-09 |
2016-04-13 |
Berry And Associates, Inc. |
Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides
|
|
WO2013085550A2
(en)
|
2011-12-05 |
2013-06-13 |
Duke University |
V1v2 immunogens
|
|
EP2788087A4
(en)
|
2011-12-06 |
2015-08-26 |
Ohio State Innovation Foundation |
Non-ionic, low-osmolar contrast agents for the administration of antisense oligonucleotides and the treatment of diseases
|
|
CN107881175B
(zh)
|
2011-12-28 |
2022-05-13 |
日本新药株式会社 |
反义核酸
|
|
TW201333040A
(zh)
|
2012-01-06 |
2013-08-16 |
Bioalliance Cv |
抗－輸鐵蛋白受器之抗體及其使用方法
|
|
NZ627896A
(en)
|
2012-01-27 |
2016-11-25 |
Biomarin Technologies B V |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
WO2013120038A2
(en)
|
2012-02-10 |
2013-08-15 |
Regents Of The University Of Minnesota |
Morpholino targeting dux4 for treating fshd
|
|
ES2812849T3
(es)
|
2012-02-24 |
2021-03-18 |
Abbvie Stemcentrx Llc |
Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
|
|
CN104379162B
(zh)
|
2012-03-15 |
2017-03-15 |
奥克西雷恩英国有限公司 |
用于治疗蓬佩氏病的方法和材料
|
|
US9610362B2
(en)
|
2012-03-16 |
2017-04-04 |
Valerion Therapeutics, Llc |
Antisense conjugates for decreasing expression of DMPK
|
|
BR112014026285B1
(pt)
|
2012-04-23 |
2021-08-31 |
Biomarin Technologies B.V |
Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento de distúrbios neuromusculares
|
|
EP3608407A1
(en)
|
2012-07-03 |
2020-02-12 |
BioMarin Technologies B.V. |
Oligonucleotide for the treatment of muscular dystrophy patients
|
|
EP2684892A1
(en)
|
2012-07-13 |
2014-01-15 |
Association Française contre les Myopathies |
Compositions and methods for duchenne muscular dystrophy gene therapy
|
|
ES2791778T3
(es)
|
2012-08-01 |
2020-11-05 |
Ikaika Therapeutics Llc |
Mitigación del daño tisular y la fibrosis a través de anticuerpos anti-LTBP4
|
|
EP2900821B1
(en)
|
2012-09-25 |
2020-04-01 |
Genzyme Corporation |
Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
|
|
EP2906699A4
(en)
|
2012-10-11 |
2016-06-08 |
Ionis Pharmaceuticals Inc |
OLIGOMER COMPOUNDS WITH BICYCLIC NUCLEOSIDES AND USES THEREOF
|
|
JP6855661B2
(ja)
|
2012-10-23 |
2021-04-07 |
シンアフィックス ビー．ブイ． |
修飾抗体、抗体コンジュゲート及びそれらを調製する方法
|
|
EP2922818B1
(en)
|
2012-11-24 |
2018-09-05 |
Hangzhou Dac Biotech Co., Ltd |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
HUE042218T2
(hu)
|
2013-03-14 |
2019-06-28 |
Sarepta Therapeutics Inc |
Exonátugrást elõsegítõ készítmények izomdisztrófia kezelésére
|
|
NZ775701A
(en)
|
2013-03-14 |
2022-08-26 |
Sarepta Therapeutics Inc |
Exon skipping compositions for treating muscular dystrophy
|
|
NZ732507A
(en)
|
2013-03-15 |
2018-08-31 |
Sarepta Therapeutics Inc |
Improved compositions for treating muscular dystrophy
|
|
EP4324480A3
(en)
|
2013-05-20 |
2024-05-08 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies and methods of use
|
|
WO2014189370A1
(en)
|
2013-05-24 |
2014-11-27 |
Stichting Katholieke Universiteit |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
JP7085716B2
(ja)
|
2013-06-05 |
2022-06-17 |
デューク ユニバーシティ |
Ｒｎａガイド遺伝子編集及び遺伝子調節
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
CN105682687A
(zh)
|
2013-08-16 |
2016-06-15 |
Rana医疗有限公司 |
异染色质形成性非编码rna
|
|
EP3033425A4
(en)
|
2013-08-16 |
2017-07-26 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin
|
|
AU2014312210A1
(en)
|
2013-08-28 |
2016-04-07 |
Abbvie Stemcentrx Llc |
Engineered anti-DLL3 conjugates and methods of use
|
|
WO2015042581A1
(en)
|
2013-09-23 |
2015-03-26 |
President And Fellows Of Harvard College |
Allele-specific rna silencing for the treatment of hypertrophic cardiomyopathy
|
|
EP3058083B1
(en)
|
2013-10-14 |
2018-04-11 |
SynAffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
EP3057618B1
(en)
|
2013-10-14 |
2022-12-14 |
SynAffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
EP2862928A1
(en)
|
2013-10-18 |
2015-04-22 |
Université de Strasbourg |
Dynamin 2 inhibitor for the treatment of centronuclear myopathies
|
|
US10004814B2
(en)
|
2013-11-11 |
2018-06-26 |
Sirna Therapeutics, Inc. |
Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
|
|
WO2015073848A1
(en)
|
2013-11-14 |
2015-05-21 |
Shehadeh Lina A |
Methods and compositions employing an osteopontin aptamer to deliver nucleic acids into smooth muscle, endothelial, cardiac and progenitor/stem cells
|
|
EP3097079B1
(en)
|
2014-01-24 |
2021-05-12 |
SynAffix B.V. |
Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne
|
|
US10266502B2
(en)
|
2014-01-24 |
2019-04-23 |
Synaffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
WO2015134365A2
(en)
|
2014-03-03 |
2015-09-11 |
Acharjee Sujata |
Chimeric dystrophin-vsv-g-protein to treat dystrophinopathies
|
|
TR201901939T4
(tr)
|
2014-03-12 |
2019-03-21 |
Nat Center Neurology & Psychiatry |
Antisens nükleik asit.
|
|
EP3119909B1
(en)
|
2014-03-18 |
2019-11-13 |
Fred Hutchinson Cancer Research Center |
Dux4-induced gene expression in facioscapulohumeral muscular dystrophy (fshd)
|
|
CA2946983A1
(en)
|
2014-04-25 |
2015-10-29 |
Yamaha Motor Power Products Kabushiki Kaisha |
Engine
|
|
JP6750148B2
(ja)
|
2014-04-25 |
2020-09-02 |
公益財団法人野口研究所 |
糖鎖切断抗体の製造方法及び均一糖鎖抗体
|
|
TWI787678B
(zh)
|
2014-05-23 |
2022-12-21 |
美商健臻公司 |
藉由使用反義寡核苷酸創造提前終止密碼子抑制或下調肝醣合成酶
|
|
EP3159409B1
(en)
|
2014-06-17 |
2019-12-04 |
Nippon Shinyaku Co., Ltd. |
Antisense nucleic acid for use in the treatment of duchenne's muscular dystrophy
|
|
AU2015301221B2
(en)
|
2014-08-04 |
2020-07-02 |
MiRagen Therapeutics, Inc. |
Inhibitors of MYH7B and uses thereof
|
|
US11046988B2
(en)
|
2014-08-04 |
2021-06-29 |
Synaffix B.V. |
Process for the modification of a glycoprotein using a β-(1,4)-N-acetylgalactosaminyl transferase or a mutant thereof
|
|
AU2015301809A1
(en)
|
2014-08-11 |
2017-02-02 |
Shire Human Genetic Therapies, Inc. |
Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
|
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
|
DK3201320T5
(da)
|
2014-09-30 |
2024-10-14 |
Amicus Therapeutics Inc |
Højpotent sur alfa-glucosidase med forbedrede carbohydrater
|
|
ES2740907T3
(es)
|
2014-10-03 |
2020-02-07 |
Synaffix Bv |
Enlazador de sulfamida, conjugados de los mismos y métodos de preparación
|
|
CA2967830A1
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
Tfr selective binding compounds and related methods
|
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
|
AU2015349890B2
(en)
|
2014-11-21 |
2018-08-30 |
Merck Sharp & Dohme Llc |
Insulin receptor partial agonists
|
|
US20190002876A1
(en)
|
2014-12-09 |
2019-01-03 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treatment of friedreich's ataxia
|
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
|
US20180216111A1
(en)
|
2015-02-27 |
2018-08-02 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
|
EP3134520B1
(en)
|
2015-04-23 |
2017-12-20 |
Synaffix B.V. |
Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a (1,4)-n-acetylgalactosaminyltransferase
|
|
TWI787796B
(zh)
|
2015-05-04 |
2022-12-21 |
美商Ｃｙｔｏｍｘ生物製藥公司 |
抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
|
|
NZ737757A
(en)
|
2015-05-19 |
2023-07-28 |
Sarepta Therapeutics Inc |
Peptide oligonucleotide conjugates
|
|
EA039366B1
(ru)
|
2015-06-24 |
2022-01-19 |
Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. |
Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
|
|
RU2737637C2
(ru)
|
2015-07-22 |
2020-12-01 |
Инатерис |
Антитела против tfr и их применение при лечении пролиферативных и воспалительных расстройств
|
|
SMT202000379T1
(it)
|
2015-09-15 |
2020-09-10 |
Nippon Shinyaku Co Ltd |
Acido nucleico antisenso
|
|
WO2017049157A1
(en)
|
2015-09-18 |
2017-03-23 |
Duke University |
Methods and compositions for the treatment of steatosis-associated disorders
|
|
US20180237775A1
(en)
|
2015-09-21 |
2018-08-23 |
Association Institut De Myologie |
Antisense oligonucleotides and uses thereof
|
|
WO2017049407A1
(en)
|
2015-09-23 |
2017-03-30 |
UNIVERSITé LAVAL |
Modification of the dystrophin gene and uses thereof
|
|
MA45819A
(fr)
|
2015-10-09 |
2018-08-15 |
Sarepta Therapeutics Inc |
Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
|
|
SG10201912902TA
(en)
|
2015-10-09 |
2020-02-27 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
CN108348621A
(zh)
|
2015-11-05 |
2018-07-31 |
竹治疗股份有限公司 |
用于基因治疗的经修饰的弗里德赖希共济失调基因及载体
|
|
MX2018007061A
(es)
|
2015-12-08 |
2018-08-15 |
Regeneron Pharma |
Composiciones y metodos para enzimas de internalizacion.
|
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
|
NZ742916A
(en)
|
2015-12-18 |
2023-03-31 |
Eisai R&D Man Co Ltd |
C-terminal lysine conjugated immunoglobulins
|
|
US10874746B2
(en)
|
2016-02-08 |
2020-12-29 |
Synaffix B.V. |
Sulfamide linkers for use in bioconjugates
|
|
JP7366541B2
(ja)
|
2016-02-19 |
2023-10-23 |
コード バイオセラピューティクス インコーポレイテッド |
核酸キャリア及び治療上の使用方法
|
|
CA3019128A1
(en)
|
2016-03-30 |
2017-10-05 |
Amicus Therapeutics, Inc. |
Formulations comprising recombinant acid alpha-glucosidase
|
|
KR102343162B1
(ko)
|
2016-03-30 |
2021-12-23 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
고 m6p 재조합 단백질의 선택 방법
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
JP7253379B2
(ja)
|
2016-04-02 |
2023-04-06 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
組織特異的発現のための改変ｕ６プロモーターシステム
|
|
FR3049951A1
(fr)
|
2016-04-12 |
2017-10-13 |
Univ Rabelais Francois |
Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
|
|
EP3445405A4
(en)
|
2016-04-18 |
2019-12-18 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGOMERS AND METHOD FOR USE THEREOF TO TREAT DISEASES RELATING TO THE ACID ALPHA GLUCOSIDASE GENE
|
|
MA45290A
(fr)
|
2016-05-04 |
2019-03-13 |
Wave Life Sciences Ltd |
Procédés et compositions d'agents biologiquement actifs
|
|
US10953076B2
(en)
|
2016-05-24 |
2021-03-23 |
Merck Sharp & Dohme Corp. |
Insulin receptor partial agonists and GLP-1 analogues
|
|
US11013757B2
(en)
|
2016-06-03 |
2021-05-25 |
Wave Life Sciences Ltd. |
Oligonucleotides, compositions and methods thereof
|
|
CN109310765A
(zh)
*
|
2016-06-20 |
2019-02-05 |
领先基因生物技术股份有限公司 |
抗体-药物偶联物
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
KR20230175312A
(ko)
|
2016-07-05 |
2023-12-29 |
바이오마린 테크놀로지스 비.브이. |
유전적 장애 치료를 위한, 특징이 개선된, 비사이클릭 스캐폴드 모이어티를 포함하는 프리-mrna 스플라이스 스위칭 또는 조정 올리고뉴클레오티드
|
|
WO2018014042A1
(en)
|
2016-07-15 |
2018-01-18 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dystrophin transcript
|
|
EP3487523B1
(en)
|
2016-07-19 |
2023-09-06 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
EP3293259A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
MX2019002842A
(es)
|
2016-09-12 |
2019-08-29 |
Genethon |
Variantes de alfa-glucosidasa acida y usos de las mismas.
|
|
US10933081B2
(en)
|
2016-09-21 |
2021-03-02 |
Alnylam Pharmaceuticals, Inc. |
Myostatin iRNA compositions and methods of use thereof
|
|
ES3038159T3
(en)
|
2016-11-16 |
2025-10-09 |
Academisch Ziekenhuis Leiden |
Substances for targeting various selected organs or tissues
|
|
US10947540B2
(en)
|
2016-11-29 |
2021-03-16 |
Association Institut De Myologie |
Allele-specific silencing therapy for Dynamin 2-related diseases
|
|
CA3044531A1
(en)
|
2016-11-28 |
2018-05-31 |
The Board Of Regents Of The University Of Texas System |
Prevention of muscular dystrophy by crispr/cpf1-mediated gene editing
|
|
AU2017370730A1
(en)
|
2016-12-08 |
2019-06-27 |
The Board Of Regents Of The University Of Texas System |
DMD reporter models containing humanized duschene muscular dystrophy mutations
|
|
WO2018118627A1
(en)
|
2016-12-19 |
2018-06-28 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
JP6956741B2
(ja)
|
2016-12-26 |
2021-11-02 |
Ｊｃｒファーマ株式会社 |
血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体
|
|
KR102471458B1
(ko)
|
2016-12-28 |
2022-11-25 |
제이씨알 파마 가부시키가이샤 |
동결건조 제제
|
|
JOP20190166A1
(ar)
|
2017-01-05 |
2019-07-02 |
Univ Texas |
استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
|
|
WO2018129384A1
(en)
|
2017-01-06 |
2018-07-12 |
Avidity Biosciences Llc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
|
WO2018140831A2
(en)
|
2017-01-27 |
2018-08-02 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
CN110809583A
(zh)
|
2017-06-07 |
2020-02-18 |
瑞泽恩制药公司 |
用于内化酶的组合物和方法
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
CA3099522C
(en)
|
2017-09-19 |
2024-10-08 |
Univ Alberta |
GAPMERES AND METHODS OF USING THESE FOR THE TREATMENT OF MUSCULAR DYSTROPHY
|
|
KR20250065737A
(ko)
|
2017-09-22 |
2025-05-13 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
US20210145852A1
(en)
|
2017-09-28 |
2021-05-20 |
Sarepta Therapeutics, Inc. |
Combination Therapies for Treating Muscular Dystrophy
|
|
US20200248178A1
(en)
|
2017-09-28 |
2020-08-06 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
EP3668997A4
(en)
|
2017-10-02 |
2021-05-19 |
Research Institute at Nationwide Children's Hospital |
SYSTEM FOR MIRNA DETARGETING FOR TISSUE-SPECIFIC INTERFERENCE
|
|
SG11202003126VA
(en)
|
2017-10-04 |
2020-05-28 |
Avidity Biosciences Inc |
Nucleic acid-polypeptide compositions and uses thereof
|
|
US11555189B2
(en)
|
2017-10-18 |
2023-01-17 |
Sarepta Therapeutics, Inc. |
Antisense oligomer compounds
|
|
WO2019092507A2
(en)
|
2017-11-09 |
2019-05-16 |
Crispr Therapeutics Ag |
Crispr/cas systems for treatment of dmd
|
|
WO2019110725A1
(en)
|
2017-12-06 |
2019-06-13 |
Synaffix B.V. |
Enediyne conjugates
|
|
CN118667812A
(zh)
|
2017-12-06 |
2024-09-20 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
US20210095283A1
(en)
|
2018-01-04 |
2021-04-01 |
Avidity Biosciences, Inc. |
Heteroduplex nucleic acid molecules and uses thereof
|
|
EP3735462A1
(en)
|
2018-01-05 |
2020-11-11 |
The Board of Regents of The University of Texas System |
Therapeutic crispr/cas9 compositions and methods of use
|
|
BR112020015617A2
(pt)
|
2018-01-31 |
2021-01-05 |
The Board Of Regents Of The University Of Texas System |
Composições e métodos para correção de mutações da distrofina em cardiomiócitos humanos
|
|
WO2019152820A1
(en)
|
2018-02-02 |
2019-08-08 |
Fred Hutchinson Cancer Research Center |
Methods for treating facioscapulohumeral muscular dystrophy
|
|
KR20200116952A
(ko)
|
2018-02-05 |
2020-10-13 |
제이씨알 파마 가부시키가이샤 |
약제를 근육에 송달하기 위한 방법
|
|
KR20200118151A
(ko)
|
2018-02-07 |
2020-10-14 |
리제너론 파마슈티칼스 인코포레이티드 |
치료 단백질 전달을 위한 방법 및 조성물
|
|
AU2019252680B2
(en)
|
2018-04-12 |
2025-11-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
WO2019209764A2
(en)
|
2018-04-26 |
2019-10-31 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers and oligomer conjugates for muscular dystrophy
|
|
WO2019215175A1
(en)
|
2018-05-08 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
SG11202010841QA
(en)
|
2018-05-11 |
2020-11-27 |
Alpha Anomeric Sas |
Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
|
|
CA3098624A1
(en)
|
2018-05-11 |
2019-11-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
US20220251551A1
(en)
|
2018-06-13 |
2022-08-11 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystrophy
|
|
WO2019246480A1
(en)
|
2018-06-21 |
2019-12-26 |
The Board Of Regents Of The University Of Texas System |
Correction of dystrophin exon 43, exon 45, or exon 52 deletions in duchenne muscular dystrophy
|
|
EP3829594A4
(en)
|
2018-08-02 |
2022-05-11 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
WO2020028844A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating centronuclear myopathy
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
MX2021001283A
(es)
|
2018-08-02 |
2021-07-15 |
Dyne Therapeutics Inc |
Complejos dirigidos al músculo y sus usos para tratar la distrofia miotónica.
|
|
WO2020028836A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
EP3829645A4
(en)
|
2018-08-02 |
2022-05-18 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF PROGRESSIVE FIBRODYSPLASIA OSSIFIANS
|
|
JP2021533200A
(ja)
|
2018-08-02 |
2021-12-02 |
ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. |
顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
EA202190417A1
(ru)
|
2018-08-02 |
2021-06-23 |
Дайн Терапьютикс, Инк. |
Мышечно-специфические комплексы и их применение для лечения болезни помпе
|
|
US20210308273A1
(en)
|
2018-08-02 |
2021-10-07 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
KR20210086601A
(ko)
|
2018-08-02 |
2021-07-08 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 프리드라이히 운동실조를 치료하기 위한 그의 용도
|
|
CN112930197A
(zh)
|
2018-08-02 |
2021-06-08 |
达因疗法公司 |
肌肉靶向复合物及其用途
|
|
US11708569B2
(en)
|
2018-08-29 |
2023-07-25 |
University Of Copenhagen |
Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid
|
|
IT201800009682A1
(it)
|
2018-10-22 |
2020-04-22 |
Ice Spa |
Coniugati di acidi biliari e loro derivati per la veicolazione di molecole attive
|
|
EP3876998A1
(en)
|
2018-11-05 |
2021-09-15 |
Synaffix B.V. |
Antibody-conjugates for targeting of tumours expressing trop-2
|
|
JP2022513719A
(ja)
|
2018-12-06 |
2022-02-09 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物及びその方法
|
|
IL319265A
(en)
|
2018-12-21 |
2025-04-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and their uses
|
|
JP2022516515A
(ja)
|
2018-12-31 |
2022-02-28 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Ｒｎａ標的化ｃｒｉｓｐｒ－ｃａｓ１３ｂを使用するｄｕｘ４ ｒｎａ発現停止
|
|
BR112021018801A2
(pt)
|
2019-03-28 |
2021-11-23 |
Sarepta Therapeutics Inc |
Métodos para tratar a distrofia muscular com casimersen
|
|
CN113677374A
(zh)
|
2019-04-08 |
2021-11-19 |
国立大学法人东京医科齿科大学 |
肌疾病治疗用药物组合物
|
|
US20220193246A1
(en)
|
2019-04-18 |
2022-06-23 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
CA3137715A1
(en)
|
2019-04-25 |
2020-10-29 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
KR20220019259A
(ko)
|
2019-06-06 |
2022-02-16 |
어비디티 바이오사이언시스 인크. |
Una 아미다이트 및 이의 용도
|
|
JP7592034B2
(ja)
|
2019-06-06 |
2024-11-29 |
アビディティー バイオサイエンシーズ，インク． |
核酸ポリペプチド組成物およびその使用
|
|
WO2020247738A1
(en)
|
2019-06-07 |
2020-12-10 |
Dyne Therapeutics, Inc. |
Methods of preparing protein-oligonucleotide complexes
|
|
EP3987029A1
(en)
|
2019-06-19 |
2022-04-27 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
|
US20220288218A1
(en)
|
2019-07-09 |
2022-09-15 |
The Governors Of The University Of Alberta |
Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the dmd gene
|
|
WO2021076856A1
(en)
|
2019-10-18 |
2021-04-22 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
EP4065225A1
(en)
|
2019-11-27 |
2022-10-05 |
DTX Pharma, Inc. |
Compounds and methods for the treatment of duchenne muscular dystrophy
|
|
WO2021127457A1
(en)
|
2019-12-20 |
2021-06-24 |
Codexis, Inc. |
Engineered acid alpha-glucosidase variants
|
|
EP4087878A4
(en)
|
2020-01-10 |
2024-06-05 |
Dyne Therapeutics, Inc. |
MUSCLE-TARGETED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
|
|
BR112022013686A2
(pt)
|
2020-01-10 |
2022-09-06 |
Dyne Therapeutics Inc |
Complexos de direcionamento a músculo e usos dos mesmos para tratar distrofia miotônica
|
|
WO2021142217A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Thereapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of milck1
|
|
CN115335062A
(zh)
|
2020-01-10 |
2022-11-11 |
达因疗法公司 |
肌肉靶向复合物及其用于调节与肌肉健康相关的基因的用途
|
|
US20230203180A1
(en)
|
2020-01-10 |
2023-06-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
WO2021142260A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of acvr1
|
|
WO2021142269A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
|
|
US20230088865A1
(en)
|
2020-01-10 |
2023-03-23 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
WO2021142331A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
|
|
CA3163608A1
(en)
|
2020-01-10 |
2021-07-15 |
Romesh R. Subramanian |
Muscle-targeting complexes and uses thereof
|
|
WO2021150382A1
(en)
|
2020-01-24 |
2021-07-29 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
WO2021154477A1
(en)
|
2020-01-31 |
2021-08-05 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
MX2022009418A
(es)
|
2020-01-31 |
2022-08-25 |
Dyne Therapeutics Inc |
Anticuerpo del receptor anti-transferrina (tfr) y usos del mismo.
|
|
EP4121063A4
(en)
|
2020-03-19 |
2024-07-03 |
Avidity Biosciences, Inc. |
COMPOSITIONS AND METHODS FOR TREATING FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY
|
|
JP7748962B2
(ja)
|
2020-03-27 |
2025-10-03 |
アビディティー バイオサイエンシーズ，インク． |
筋ジストロフィーを処置するための組成物および方法
|
|
EP4146229A4
(en)
|
2020-05-05 |
2025-07-23 |
Avidity Biosciences Inc |
COMPOSITIONS AND METHODS FOR TREATING POMPE DISEASE
|
|
KR20230041760A
(ko)
|
2020-07-23 |
2023-03-24 |
다인 세라퓨틱스, 인크. |
항-트랜스페린 수용체 (tfr) 항체 및 그의 용도
|
|
JP2023535078A
(ja)
|
2020-07-23 |
2023-08-15 |
ダイン セラピューティクス，インコーポレーテッド |
筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用
|
|
EP4185320A4
(en)
|
2020-07-23 |
2025-10-08 |
Dyne Therapeutics Inc |
MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY
|
|
EP4185314A4
(en)
|
2020-07-23 |
2024-08-07 |
Dyne Therapeutics, Inc. |
MUSCLE-TARGETED COMPLEXES AND USES THEREOF FOR THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
|
|
JP2023535073A
(ja)
|
2020-07-23 |
2023-08-15 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
|
|
AU2021313058A1
(en)
|
2020-07-23 |
2023-03-30 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof
|
|
EP4208548A4
(en)
|
2020-09-01 |
2025-10-22 |
Ultragenyx Pharmaceutical Inc |
DUX4 INHIBITORS AND METHODS OF USE
|
|
KR20230079068A
(ko)
|
2020-09-03 |
2023-06-05 |
다인 세라퓨틱스, 인크. |
단백질-올리고뉴클레오티드 복합체의 제조 방법
|
|
WO2022056266A2
(en)
|
2020-09-11 |
2022-03-17 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
|
|
US20240026356A1
(en)
|
2020-11-30 |
2024-01-25 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd)
|
|
KR20230117182A
(ko)
|
2020-12-04 |
2023-08-07 |
다인 세라퓨틱스, 인크. |
항체-올리고뉴클레오티드 복합체 및 그의 용도
|
|
EP4271816A4
(en)
|
2020-12-31 |
2025-04-02 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND RELATED USES FOR THE TREATMENT OF MYOTONIC DYSTROPHY
|
|
WO2022147207A1
(en)
|
2020-12-31 |
2022-07-07 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US20240336915A1
(en)
|
2021-01-22 |
2024-10-10 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing dux4 expression
|
|
MX2023011612A
(es)
|
2021-03-31 |
2023-12-15 |
Entrada Therapeutics Inc |
Peptidos de penetracion celular ciclicos.
|
|
EP4314298A1
(en)
|
2021-04-02 |
2024-02-07 |
Avidity Biosciences, Inc. |
Antibody-oligonucleotide conjugate and antibody-peptide-oligonucleotide conjugate compositions and methods of inducing exon skipping
|
|
WO2022217366A1
(en)
|
2021-04-14 |
2022-10-20 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Modified oligonucleotides for the treatment of duchenne muscular dystrophy
|
|
AU2022267324A1
(en)
|
2021-04-30 |
2023-12-14 |
Sarepta Therapeutics, Inc. |
Treatment methods for muscular dystrophy
|
|
WO2022271543A2
(en)
|
2021-06-21 |
2022-12-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating friedreich's ataxia
|
|
EP4359534A1
(en)
|
2021-06-21 |
2024-05-01 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
AU2022298028A1
(en)
|
2021-06-23 |
2023-12-21 |
National Center Of Neurology And Psychiatry |
Combination of antisense oligomers
|
|
US11648318B2
(en)
|
2021-07-09 |
2023-05-16 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (TFR) antibody and uses thereof
|
|
EP4366784A1
(en)
|
2021-07-09 |
2024-05-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating dystrophinopathies
|
|
KR20240035826A
(ko)
|
2021-07-09 |
2024-03-18 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
|
|
JP2024525613A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびジストロフィノパチーを処置するためのその使用
|
|
CN118355035A
(zh)
|
2021-07-09 |
2024-07-16 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗肌养蛋白病的用途
|
|
EP4367142A4
(en)
|
2021-07-09 |
2025-08-27 |
Dyne Therapeutics Inc |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF DYSTROPHINOPATHIES
|
|
EP4367247A4
(en)
|
2021-07-09 |
2025-08-27 |
Dyne Therapeutics Inc |
MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF DYSTROPHINOPATHIES
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
CA3226361A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2023283629A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
AU2022306307A1
(en)
|
2021-07-09 |
2024-02-01 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
JPWO2023022229A1
(enExample)
|
2021-08-19 |
2023-02-23 |
|
|
|
JPWO2023026994A1
(enExample)
|
2021-08-21 |
2023-03-02 |
|
|
|
CA3230279A1
(en)
|
2021-09-01 |
2023-03-09 |
Xiang Li |
Compositions and methods for skipping exon 45 in duchenne muscular dystrophy
|
|
KR20240055874A
(ko)
|
2021-09-16 |
2024-04-29 |
어비디티 바이오사이언시스 인크. |
안면견갑상완 근이영양증을 치료하는 조성물 및 방법
|
|
MX2024003373A
(es)
|
2021-09-16 |
2024-04-04 |
Dyne Therapeutics Inc |
Dosis de complejos dirigidos a musculos para el tratamiento de distrofinopatias.
|
|
IL312142A
(en)
|
2021-11-01 |
2024-06-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes for the treatment of dystrophinopathy
|
|
EP4429711A1
(en)
|
2021-11-12 |
2024-09-18 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy
|
|
EP4452331B8
(en)
|
2021-12-22 |
2025-09-17 |
Sapreme Technologies B.V. |
Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
|
|
WO2023121444A1
(en)
|
2021-12-22 |
2023-06-29 |
Sapreme Technologies B.V. |
Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders
|
|
JP2025500481A
(ja)
|
2021-12-22 |
2025-01-09 |
サプリーム テクノロジーズ，ベー．フェー． |
筋消耗性障害を治療するための治療用核酸とサポニンとを含む組成物
|
|
EP4469576A1
(en)
|
2022-01-27 |
2024-12-04 |
The Governors of the University of Alberta |
Pre-mrna slice modulating peptide-conjugated antisense therapeutics for the treatment of diseases
|
|
WO2023154807A2
(en)
|
2022-02-09 |
2023-08-17 |
Locanabio, Inc. |
Compositions and methods for modulating pre-mrna splicing
|
|
WO2023168427A1
(en)
|
2022-03-03 |
2023-09-07 |
Yale University |
Compositions and methods for delivering therapeutic polynucleotides for exon skipping
|
|
JP2025079347A
(ja)
|
2022-03-11 |
2025-05-22 |
日本新薬株式会社 |
キャリアペプチドが連結された核酸
|
|
EP4493693A1
(en)
|
2022-03-17 |
2025-01-22 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer conjugates
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
WO2023201318A1
(en)
|
2022-04-15 |
2023-10-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
|
IL316206A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Dosage of muscle targeting complexes for the treatment of myotonic dystrophy
|
|
KR20250004770A
(ko)
|
2022-04-15 |
2025-01-08 |
다인 세라퓨틱스, 인크. |
근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
|
|
KR20250004769A
(ko)
|
2022-04-15 |
2025-01-08 |
다인 세라퓨틱스, 인크. |
근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 그의 용도
|
|
WO2024011150A2
(en)
|
2022-07-06 |
2024-01-11 |
Dyne Therapeutics, Inc. |
Cns targeting complexes and uses thereof
|
|
WO2024011135A2
(en)
|
2022-07-06 |
2024-01-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
WO2024064237A2
(en)
|
2022-09-21 |
2024-03-28 |
Sarepta Therapeutics, Inc. |
Dmd antisense oligonucleotide-mediated exon skipping efficiency
|
|
WO2024097644A1
(en)
|
2022-10-31 |
2024-05-10 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for skipping exon 45 of a dmd gene
|
|
CN120529923A
(zh)
|
2022-11-21 |
2025-08-22 |
肽世代公司 |
细胞穿透肽、其缀合物及其使用方法
|
|
AU2024208393A1
(en)
|
2023-01-10 |
2025-07-10 |
Ausperbio Therapeutics Inc. |
Modified multi-segmented antisense oligonucleotides for use
|
|
KR20250159196A
(ko)
|
2023-02-27 |
2025-11-10 |
다인 세라퓨틱스, 인크. |
근육내 섬유증의 진행을 억제하기 위한 방법 및 조성물
|